Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;19(4):303-14.

Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry

Dean Elbe  1 , Angela Macbride, Dorothy Reddy
Affiliations

Focus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry

Dean Elbe et al. J Can Acad Child Adolesc Psychiatry. 2010 Nov.

Abstract

Objective: To summarize and review published literature regarding lisdexamfetamine and its use in child and adolescent psychiatry.

Method: A LITERATURE REVIEW WAS CONDUCTED USING THE PUBMED SEARCH TERM: 'lisdexamfetamine' with limits: Human trials, English language, All Child (aged 0-18 years). Additional articles were identified from reference information and poster presentation data.

Results: Lisdexamfetamine (Vyvanse®) is a prodrug formulation of dextroamphetamine used for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Conversion of lisdexamfetamine to active dextroamphetamine occurs via hydrolytic enzymes located on erythrocytes, and leads to an onset of action within 1-2 hours post-dose, and duration of up to 13 hours. Administration of lisdexamfetamine via nasal or intravenous routes did not result in significant elevation of drug liking scores in known stimulant abusers, suggesting low potential for abuse. Lisdexamfetamine has been available in the United States since 2007, but was only recently approved by Health Canada for use in children 6 to 12 years of age. There are five randomized controlled trials with lisdexamfetamine in children and adolescents showing efficacy for treatment of ADHD. In addition, several open-label trials and case reports were identified. The adverse effect profile of lisdexamfetamine is similar to that observed with other long-acting amphetamine formulations.

Conclusion: Lisdexamfetamine is a novel long-acting stimulant formulation with efficacy for treatment of ADHD and low abuse potential due to its prodrug formulation.

Keywords: ADHD; amphetamine; attention deficit; hyperactivity; lisdexamfetamine; stimulants; substance abuse.

PubMed Disclaimer

References

    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. Revised 4th ed. Washington, DC: Author; 2000.
    1. Barrett SP, Darredeau C, Bordy LE, Pihl RO. Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry 2005. 2005;50(8):457–461. - PubMed
    1. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and Tolerability of Lisdexamfetamine Dimesylate (NRP-104) in Children with Attention-Deficit/Hyperactivity Disorder: A Phase III, Multicenter, Randomized, Double-Blind, Forced-Dose, Parallel-Group Study. Clinical Therapeutics. 2007a;29(3):450–463. - PubMed
    1. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study. Biological Psychiatry 2007. 2007b;62(9):970–976. - PubMed
    1. Boellner SW, Stark JG, Krishnan S, Zhang Y. Pharmacokinetics of Lisdexamfetamine Dimesylate and Its Active Metabolite, d-Amphetamine, With Increasing Oral Doses of Lisdexamfetamine Dimesylate in Children With Attention-Deficit/Hyperactivity Disorder: A Single-Dose, Randomized, Open-Label, Crossover Study. Clinical Therapeutics 2010. 2010;32(2):252–264. - PubMed

LinkOut - more resources